



CER1 is a common target of WNT and NODAL signaling pathways in human embryonic stem cells

MASUKO KATOH¹ and MASARU KATOH²

¹M&M Medical BioInformatics, Hongo 113-0033; ²Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan

Received January 3, 2006; Accepted February 7, 2006

Abstract. Nodal and BMP signaling pathways network with WNT signaling pathway during embryogenesis and carcinogenesis. CER1 (Cerberus 1) and GREM3 (CKTSF1B3 or CER2) inhibit NODAL signaling through ACVR1B (ALK4) or ACVR1C (ALK7) to SMAD2 or SMAD3. GREM1 (CKTSF1B1) inhibits BMP signaling through BMPR1A (ALK3), BMPR1B (ALK6) or ACVR1 (ALK2) to SMAD1, SMAD5 or SMAD8. CER1, GREM1 and GREM3 are DAN domain (DAND) family members; however, transcriptional regulation of *DAND* family members by canonical WNT signaling pathway remains unclear. We searched for the TCF/LEF-binding site within the promoter region of *DAND* family genes, including *CER1*, *GREM1*, *GREM2*, *GREM3* and *NBL1*. Because triple TCF/LEF-binding sites were identified within human *CER1* promoter by using bioinformatics and human intelligence, comparative genomics analyses on *CER1* orthologs were further performed. Chimpanzee *CER1* gene, encoding 267-amino-acid protein, was identified within NW_111298.1 genome sequence. XM_528542.1 was not a correct coding sequence for chimpanzee CER1. Primate CER1 orthologs were significantly divergent from rodent Cer1 orthologs. Three TCF/LEF-binding sites within human *CER1* promoter were conserved in chimpanzee *CER1* promoter, two in cow and dog *Cer1* promoters, but not in rodent *Cer1* promoters. Binding sites for NODAL signaling effectors, SMAD3/SMAD4 and FOXH1, were also conserved among human, chimpanzee, cow and dog *CER1* promoters. *CER1* orthologs were evolutionarily conserved target of WNT and NODAL signaling pathways in non-rodent mammals. Human *CER1* mRNA was expressed in embryonic stem (ES) cells in the undifferentiated state and in the early endodermal lineage. CER1 upregulation in human ES cells leads to Nodal signaling inhibition associated with differentiation of human ES cells. Primate CER1 orthologs, playing a pivotal role during early

embryogenesis, underwent protein evolution as well as promoter evolution. These facts indicate that molecular evolution of *CER1* orthologs contributes to the significantly divergent scenarios of early embryogenesis in primates and rodents.

Introduction

TGFB1, *TGFB2*, *TGFB3*, *NODAL*, *LEFTY1*, *LEFTY2*, *INHA*, *INHBA*, *INHBB*, *INHBC*, *INHBE*, *AMH*, *BMP2*, *BMP3*, *BMP4*, *BMP5*, *BMP6*, *BMP7*, *BMP8A*, *BMP8B*, *BMP10*, *BMP15*, *GDF1*, *GDF2*, *GDF3*, *GDF5*, *GDF6*, *GDF7*, *GDF8*, *GDF9*, *GDF10*, *GDF11*, and *GDF15* are TGF β superfamily genes within the human genome (<http://www.gene.ucl.ac.uk>). TGF β signals are transduced through type I receptor TGFBR1 and type II receptor TGFBR2 to phosphorylate R-SMAD proteins, such as SMAD2 and SMAD3 (1-5). NODAL signals are transduced through type I receptor ACVR1B/ACVR1C and type II receptor ACVR2A/ACVR2B to phosphorylate SMAD2 or SMAD3 (6-8). BMP signals are transduced through type I receptor BMPR1A/BMPR1B/ACVR1 and type II receptor BMPR2 to phosphorylate R-SMAD proteins, such as SMAD1, SMAD5 and SMAD8 (9-11). R-SMADs, associated with SMAD4, are translocated to the nucleus to activate transcription of target genes.

CER1 (DAND4 or Cerberus 1), GREM1 (DAND2 or CKTSF1B1), GREM2 (DAND3 or CKTSF1B2), GREM3 (DAND5 or CKTSF1B3 or CER2) and NBL1 (DAND1) are secreted-type DAN domain (DAND) proteins (12-16). CER1 and GREM3 are Nodal antagonists, while GREM1 is a BMP antagonist.

TGF β superfamily signaling pathways network with WNT signaling pathway upregulating target genes based on the TCF/LEF transcriptional complex (17-28); however, WNT-dependent transcriptional regulation of *DAND* family members remains unclear. Here, we searched for TCF/LEF-binding site within the promoter region of *DAND* family genes. Because triple TCF/LEF-binding sites were identified within human *CER1* promoter, comparative genomics analyses on *CER1* orthologs were further performed.

Materials and methods

WNT target gene screening. Genome sequences corresponding to human *CER1*, *GREM1*, *GREM2*, *GREM3* and *NBL1* genes

Correspondence to: Dr Masaru Katoh, Genetics and Cell Biology Section, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
E-mail: mkatoh@ncc.go.jp

Key words: bioinformatics, comparative genomics, comparative proteomics, WNT, Nodal, integrome network

Genetyx program revealed that nucleotide position 46-849 was the coding region of chimpanzee CER1 complete CDS (Fig. 2A). Chimpanzee *CER1* gene was found to encode a 267-amino-acid protein.

Figure 2. (A), Nucleotide and amino-acid sequences of chimpanzee CER1. Nucleotides and amino-acid residues are numbered on the right. (B), Chimpanzee *CER1* promoter. The region corresponding to exon 1 is boxed. Three TCF/LEF-binding sites as well as SMAD- and FOXH1-binding sites are shown by over-lines.




Figure 3. (A), Schematic representation of 5'-promoter region of mammalian *CER1* orthologs. Hs, human; Pt, chimpanzee; Bt, cow; Cf, dog; Mm, mouse; Rn, rat. TCF/LEF-binding site (oval), SMAD-binding site (open box) and FOXH1-binding site (closed box) are shown. Human, chimpanzee, cow and dog *CER1* orthologs are evolutionarily conserved target of WNT and NODAL signaling pathways. (B), Schematic representation of WNT and NODAL signaling pathways in human ES cells. WNT and NODAL signaling pathways are necessary for the maintenance of human ES cells, and *CER1* is the common target of WNT and NODAL signaling pathways.

Expression of human CER1 mRNA. *In silico* expression analyses were performed to investigate expression of human CER1. Human CER1 mRNA was expressed in embryonic stem (ES) cells in the undifferentiated state and in the early endodermal lineage.

Comparative genomics analyses on CER1 promoters. Human *CER1* promoter and chimpanzee *CER1* promoter were located

within AL390732.10 and NW_111298.1 genome sequences, respectively, as mentioned above. BLAST programs revealed that the cow *Cer1*, dog *Cer1*, mouse *Cer1* and rat *Cer1* promoters were located within AC173174.3, NW_876253.1, AL670958.4 and AC091341.6 genome sequences, respectively. Phylogenetic analysis on the 5'-promoter region of mammalian *CER1* orthologs revealed that human, chimpanzee, cow and dog *CER1* promoters were significantly divergent from mouse and rat *Cer1* promoters.

GC content of human *CER1* promoter was 42.8%, that of chimpanzee *CER1* promoter was 42.9%, that of cow *Cer1* promoter was 45.5%, that of dog *Cer1* promoter was 41.2%, that of mouse *Cer1* promoter was 47.0%, and that of rat *Cer1* promoter were 47.7%. GC content of human, chimpanzee, cow and dog *CER1* promoters were lower than those of mouse and rat *Cer1* promoters.

Three TCF/LEF-binding sites within human *CER1* promoter were conserved in chimpanzee *CER1* promoter, two in cow and dog *Cer1* promoters, but not in rodent *Cer1* promoters (Fig. 3A).

Because WNT and NODAL signaling pathways play a key role in the maintenance of human ES cells (47), we next investigated the binding sites for NODAL signaling effectors, SMAD3/SMAD4 and FOXH1. SMAD3/SMAD4-binding site was conserved among mammalian *CER1* promoters. On the other hand, FOXH1-binding site was conserved only among human, chimpanzee, cow and dog *CER1* promoters, but not in mouse and rat *Cer1* promoters (Fig. 3A).

These facts indicate that *CER1* orthologs were evolutionarily conserved target of WNT and NODAL signaling pathways in human, chimpanzee, cow and dog.

Discussion

TCF/LEF-binding site within the promoter region of *DAND* family genes, including *CER1*, *GREM1*, *GREM2*, *GREM3* and *NBL1*, were searched for by using bioinformatics and human intelligence in this study. Because triple TCF/LEF-binding sites were identified within human *CER1* promoter (Fig. 1B), comparative genomics analyses on *CER1* orthologs were further performed.

Chimpanzee *CER1* gene, consisting of two exons, was identified within NW_111298.1 genome sequence. Because XM_528542.1 was not a correct coding sequence for chimpanzee *CER1*, complete CDS of chimpanzee *CER1* was determined by assembling exonic regions (Fig. 2A). Chimpanzee *CER1* gene was found to encode a 267-amino-acid protein showing 97.8% and 68.5% total-amino-acid identity with human *CER1* and mouse *Cer1*, respectively. Phylogenetic analysis on human and mouse *DAND* family members next revealed that human *CER1* and mouse *Cer1* were significantly divergent (Fig. 1C). These facts clearly indicate that the *CER1* protein evolution has occurred during mammalian evolution.

Three TCF/LEF-binding sites within human *CER1* promoter were conserved in chimpanzee *CER1* promoter, two sites in cow and dog *Cer1* promoters, but no site in rodent *Cer1* promoters (Fig. 3A). Binding sites for NODAL signaling effectors, SMAD3/SMAD4 and FOXH1, were also conserved among human, chimpanzee, cow and dog *CER1* promoters

(Fig. 3A). Based on these facts, non-rodent mammalian *CER1* orthologs were identified as the evolutionarily conserved target of WNT and NODAL signaling pathways.

CER1 mRNA was expressed in human ES cells in the undifferentiated state and in the early endodermal lineage as mentioned in the Results. WNT and NODAL signaling pathways are indispensable for human ES cells (47), and *CER1* is the common target of WNT and NODAL signaling pathways (Fig. 3B). Because *CER1* upregulation in human ES cells leads to Nodal signaling inhibition associated with endodermal differentiation, *CER1* is a key molecule for the maintenance of human ES cells. *CER1* is the pharmacogenomics target in the field of regenerative medicine.

Primate *CER1* orthologs, playing a pivotal role during early embryogenesis, underwent protein evolution as well as promoter evolution. These facts indicate that molecular evolution of *CER1* orthologs contributes to the significantly divergent scenarios of early embryogenesis in primates and rodents.

References

- Heldin CH, Miyazono K and ten Dijke P: TGF β signaling from cell membrane to nucleus through SMAD proteins. *Nature* 390: 465-471, 1997.
- Massague J: TGF β signal transduction. *Annu Rev Biochem* 67: 753-791, 1998.
- Massague J: How cells read TGF β signals. *Nat Rev Mol Cell Biol* 1: 169-178, 2000.
- Moustakas A, Souchelnytskyi S and Heldin CH: Smad regulation in TGF β signal transduction. *J Cell Sci* 114: 4359-4369, 2001.
- Miyazono K, ten Dijke P and Heldin CH: Divergence and convergence of TGF β /BMP signaling. *J Cell Physiol* 187: 265-276, 2001.
- Whiteman M: Nodal signaling in early vertebrate embryos: themes and variations. *Dev Cell* 1: 605-617, 2001.
- Reissmann E, Jornvall H, Blokzijl A, *et al*: The orphan receptor ALK7 and Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. *Genes Dev* 15: 2010-2022, 2001.
- Norris DP, Brennan J, Bikoff EK and Robertson EJ: The Foxh1-dependent autoregulatory enhancer controls the level of Nodal signaling in the mouse embryo. *Development* 129: 3455-3468, 2002.
- Zhang J and Li L: BMP signaling and stem cell regulation. *Dev Biol* 284: 1-11, 2005.
- Varga AC and Wrana JL: The disparate role of BMP in stem cell biology. *Oncogene* 24: 5713-5721, 2005.
- Katoh Y and Katoh M: Comparative genomics on *BMP4* orthologs. *Int J Oncol* 27: 581-585, 2005.
- Lah M, Brodnicki T, Maccarone P, *et al*: Human *cerberus* related gene *CER1* maps to chromosome 9. *Genomics* 55: 364-366, 1999.
- Topol LZ, Modi WS, Koochekpour S and Blair DG: DRM/GREMLIN (CKTSF1B1) maps to human chromosome 15 and is highly expressed in adult and fetal brain. *Cytogenet Cell Genet* 89: 79-84, 2000.
- Katoh M and Katoh M: Identification and characterization of human *CKTSF1B2* and *CKTSF1B3* genes *in silico*. *Oncol Rep* 12: 423-427, 2004.
- Marques S, Borges AC, Silva AC, *et al*: The activity of the Nodal antagonist Cerl-2 in the mouse node is required for correct L/R body axis. *Genes Dev* 18: 2342-2347, 2004.
- Katoh M and Katoh M: Comparative genomics on *Norrie* disease gene. *Int J Mol Med* 15: 885-889, 2005.
- Katoh M: *WNT* and *FGF* gene clusters. *Int J Oncol* 21: 1269-1273, 2002.
- Katoh M: Regulation of WNT signaling molecules by retinoic acid during neuronal differentiation in NT2 cells: threshold model of WNT action. *Int J Mol Med* 10: 683-687, 2002.
- Heller RS, Klein T, Ling Z, Heimberg H, Katoh M, Madsen OD and Serup P: Expression of *WNT*, *Frizzled*, *sFRP*, and *DKK* genes in adult human pancreas. *Gene Expr* 11: 141-147, 2003.



SPANDIDOS M: WNT2 and human gastrointestinal cancer. *Int J Mol Med* 21: 811-816, 2003.

21. Katoh M and Katoh M: Identification and characterization of human *BCL9L* gene and mouse *Bcl9l* gene *in silico*. *Int J Mol Med* 12: 643-649, 2003.
22. Garciadiego-Cazares D, Rosales C, Katoh M and Chimal-Monroy J: Coordination of chondrocyte differentiation and joint formation by $\alpha 5\beta 1$ integrin in the developing appendicular skeleton. *Development* 131: 4735-4742, 2004.
23. Katoh M and Katoh M: Comparative genomics on *WNT8A* and *WNT8B* genes. *Int J Oncol* 26: 1129-1133, 2005.
24. Katoh M: Molecular evolution of *WNT2B* orthologs. *Int J Oncol* 26: 1135-1139, 2005.
25. Katoh M: Comparative genomics on *WNT3-WNT9B* gene cluster. *Int J Mol Med* 15: 743-747, 2005.
26. Swain RK, Katoh M, Medina A and Steinbeisser H: *Xenopus* frizzled-4S, a splicing variant of *Xfz4*, is a context-dependent activator and inhibitor of Wnt/ β -catenin signaling. *Cell Commun Signal* 3: 12, 2005.
27. Katoh M: Epithelial-mesenchymal transition in gastric cancer. *Int J Oncol* 27: 1677-1683, 2005.
28. Katoh M: WNT2B: comparative integromics and clinical application. *Int J Mol Med* 16: 1103-1108, 2005.
29. Katoh M: Paradigm shift in gene-finding method: from bench-top approach to desk-top approach. *Int J Mol Med* 10: 677-682, 2002.
30. Katoh M and Katoh M: Evolutionary conservation of *CCND1-ORAOVI-FGF19-FGF4* locus from zebrafish to human. *Int J Mol Med* 12: 45-50, 2003.
31. Katoh M and Katoh M: *CLDN23* gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of *CLAUDIN* gene family. *Int J Mol Med* 11: 683-689, 2003.
32. Katoh M and Katoh M: Identification and characterization of human *MPP7* gene and mouse *Mpp7* gene *in silico*. *Int J Mol Med* 13: 333-338, 2004.
33. Katoh M and Katoh M: Identification and characterization of *Crumbs* homolog 2 gene at human chromosome 9q33.3. *Int J Oncol* 24: 743-749, 2004.
34. Katoh Y and Katoh M: Comparative genomics on *DKK1* orthologs. *Int J Oncol* 27: 275-279, 2005.
35. Katoh Y and Katoh M: Comparative genomics on *DKK2* and *DKK4* orthologs. *Int J Mol Med* 16: 477-481, 2005.
36. Katoh M and Katoh M: Comparative genomics on *FGF20* orthologs. *Oncol Rep* 14: 287-290, 2005.
37. Katoh M and Katoh M: Comparative genomics on *FGF8*, *FGF17*, and *FGF18* orthologs. *Int J Mol Med* 16: 493-496, 2005.
38. Katoh Y and Katoh M: Comparative genomics on *FGF16* orthologs. *Int J Mol Med* 16: 959-963, 2005.
39. Katoh M and Katoh M: Identification and characterization of human *HES2*, *HES3*, and *HES5* genes *in silico*. *Int J Oncol* 25: 529-534, 2004.
40. Katoh M and Katoh M: Identification and characterization of human *HESL*, rat *Hesl* and rainbow trout *hesl* genes *in silico*. *Int J Mol Med* 14: 747-751, 2004.
41. Katoh M and Katoh M: Comparative genomics on *WNT5A* and *WNT5B* genes. *Int J Mol Med* 15: 749-753, 2005.
42. Katoh Y and Katoh M: Comparative genomics on *WNT11* gene. *Int J Mol Med* 15: 879-883, 2005.
43. Katoh Y and Katoh M: Comparative genomics on *VANGL1* and *VANGL2* genes. *Int J Oncol* 26: 1435-1440, 2005.
44. Katoh Y and Katoh M: Comparative genomics on *SFRP1* orthologs. *Int J Oncol* 27: 861-865, 2005.
45. Katoh Y and Katoh M: WNT antagonist, SFRP1, is Hedgehog signaling target. *Int J Mol Med* 17: 171-175, 2006.
46. Katoh Y and Katoh M: Comparative genomics on HHIP family orthologs. *Int J Mol Med* 17: 391-395, 2006.
47. James D, Levine AJ, Besser D and Hemmati-Brivanlou A: TGF β /activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. *Development* 132: 1273-1282, 2005.